MiMedx Group Q1 2024 Adj EPS $0.07 Beats $0.04 Estimate, Sales $84.709M Beat $79.361M Estimate
Portfolio Pulse from Benzinga Newsdesk
MiMedx Group (NASDAQ:MDXG) reported Q1 2024 adjusted EPS of $0.07, surpassing the $0.04 estimate, and sales of $84.709M, exceeding the $79.361M estimate. This represents a significant improvement over the previous year, with a 333.33% increase in EPS from a loss of $(0.03) and an 18.18% increase in sales from $71.676M.
April 30, 2024 | 8:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MiMedx Group reported a strong Q1 2024 with adjusted EPS of $0.07, beating estimates, and sales of $84.709M, also above expectations. This performance indicates a significant turnaround from the previous year's losses.
MiMedx Group's Q1 2024 earnings and sales not only surpassed analyst expectations but also showed a remarkable improvement from the previous year's losses. This positive performance is likely to instill investor confidence and could lead to a short-term uptick in MDXG's stock price, given the substantial beat on both the top and bottom lines.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100